CTI Biopharma Corp reports results for the quarter ended in December - Earnings Summary

CTI Biopharma

31/03/2022 22:25

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss
of 38 cents​​ per share for the quarter ended in December. The
mean expectation of six analysts for the quarter was for a loss
of 28 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * CTI Biopharma Corp's reported EPS for the quarter was a
loss
of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.1%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * CTI Biopharma Corp shares had risen by 102.0% this
quarter.
    * The company reported a quarterly loss of $36.79 million.
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $8.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 31 at 09:24 p.m.  ​All
figures in US dollars unless otherwise stated